Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
McKinsey
Cantor Fitzgerald
Fuji
Accenture
Merck
McKesson
Moodys

Generated: October 21, 2018

DrugPatentWatch Database Preview

JUBLIA Drug Profile

« Back to Dashboard

When do Jublia patents expire, and what generic alternatives are available?

Jublia is a drug marketed by Dow Pharm and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.

Drug patent expirations by year for JUBLIA
Generic Entry Opportunity Date for JUBLIA
Generic Entry Date for JUBLIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for JUBLIA
Ingredient-typeAzoles
Drug ClassAzole Antifungal
Synonyms for JUBLIA
(2R, 3R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidyl)-1-(1,2,4-triazolyl)butan-2-ol
(2R,3R)-2-(2,4-Difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1H-1,2,4-triazin-1-il)butan-2-ol
(2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidyl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)butane-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidino)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
(2r,3r)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
1-Piperidineethanol, alpha-(2,4-difluorophenyl)-beta-methyl-4-methylene-alpha-(1H-1,2,4-triazol-1- ylmethyl)-, (alphaR,betaR)-
164650-44-6
164905-19-5
2856AH
AC1LAJ21
AK315814
AKOS027323571
C18H22F2N4O
CHEBI:82718
CHEMBL2103877
Clenafin (TN)
CS-3500
CTK5J2975
D0G4BI
D10021
DB09040
DTXSID40167787
efinaconazol
EFINACONAZOLE
Efinaconazole (JAN/USAN/INN)
Efinaconazole [USAN:INN]
Efinaconazole(KP-103)
efinaconazolum
HSDB 8341
HY-15660
IDP-108
J82SB7FXWB
Jublia (TN)
KB-145948
KP-103
KP103
KS-00000SEK
MFCD00936407
MolPort-039-139-376
NFEZZTICAUWDHU-RDTXWAMCSA-N
SCHEMBL300738
UNII-J82SB7FXWB
ZINC6251

US Patents and Regulatory Information for JUBLIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dow Pharm JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Dow Pharm JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Dow Pharm JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Dow Pharm JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Dow Pharm JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for JUBLIA
Drugname Dosage Strength RLD Date
➤ Subscribe Topical Solution 10% ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
McKinsey
Cantor Fitzgerald
Fuji
Accenture
Merck
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.